Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0016719 (
Friedreich's ataxia
)
2,098
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Seven patients, six suffering from amyotrophic lateral sclerosis (ALS) and one from
Friedreich ataxia
, were treated with a placebo i.v. infusion during the first day and with
TRH
-T i.v. infusion at a rate of 2 mg/h for 8 h daily (total daily dosage 16 mg) on the 2 consecutive days. Continuous blood pressure (BP) and EKG monitorings were performed during 3 days infusion. Blood samples were collected for endocrinological evaluations. The neurological evaluation after acute
TRH
-T treatment showed an objective improvement in 3 of the 8. We found significantly higher values of systolic (max. difference of 10.1 mm Hg) and diastolic (max. difference of 8.8 mm Hg) BP than during placebo, beginning from the 5th h of the infusion (p less than 0.05). A trend in progressive increase of the heart rate (HR) reached statistical significance (p less than 0.01) at the 8th h of the second
TRH
-T infusion. The cardiovascular changes during the i.v. continuous
TRH
-T infusions were clinically irrelevant and never required the interruption of the treatment.
...
PMID:Continuous intravenous infusion of TRH-T: clinical, cardiovascular and endocrinological effects. 179 54
Oral glucose tolerance, thyroid function tests, as well as thyrotropin, prolactin and growth hormone release after administration of thyrotropin releasing hormone, were evaluated in patients with
Friedreich's ataxia
and unaffected family members. Impaired glucose tolerance was found in the majority of family members, affected or not. Thyroid hormone levels and PRL and TSH responses to
TRH
, were similar in all and normal. However, GH responses to
TRH
were abnormal in half of the patients, but in none of the unaffected family members. Paradoxical responses to neuropeptides may characterize some
Friedreich's ataxia
patients, and may predict the possibility of therapeutic maneuvers with such peptides in these patients.
...
PMID:Pituitary responses to a neuroactive tripeptide (TRH) in Friedreich's ataxia families. 680 4